Silvaco Group, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Santa Clara, State of California, on March 12, 2026.
SILVACO GROUP, INC.
/s/ Dr. Walden C. Rhines
Dr. Walden C. RhinesChief Executive Officer
We, the undersigned directors and officers of Silvaco Group, Inc., hereby severally constitute and appoint Dr. Walden C. Rhines, Christopher Zegarelli and Candace Jackson, and each of them individually, with full powers of substitution and resubstitution, our true and lawful attorneys, with full powers to them and each of them to sign for us, in our names and in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K filed with the SEC, granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that any such attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Dr. Walden C. Rhines | Chief Executive Officer and Director(Principal Executive Officer) | March 12, 2026 |
| Dr. Walden C. Rhines | ||
| /s/ Christopher Zegarelli | Chief Financial Officer(Principal Financial and Accounting Officer) | March 12, 2026 |
| Christopher Zegarelli | ||
| /s/ Katherine S. Ngai-Pesic | Chair of the Board | March 12, 2026 |
| Katherine S. Ngai-Pesic | ||
| /s/ Dr. Hau L. Lee | Lead Independent Director | March 12, 2026 |
| Dr. Hau L. Lee | ||
| /s/ Anita Ganti | Director | March 12, 2026 |
| Anita Ganti | ||
| /s/ William H. Molloie, Jr. | Director | March 12, 2026 |
| William H. Molloie, Jr. | ||
| /s/ Anthony K. K. Ngai | Director | March 12, 2026 |
| Anthony K. K. Ngai | ||
| /s/ Iliya Pesic | Director | March 12, 2026 |
| Iliya Pesic | ||
| /s/ Jodi L. Shelton | Director | March 12, 2026 |
| Jodi L. Shelton | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.